Variantyx Secures $20M in Series C Funding

16 Mar, 2021

Variantyx Secures $20M in Series C Funding
Photo by Asaf Gazit on Unsplash

– Variantyx, a Boston, MA-based hereditary disease testing company, secured $20M in Series C funding.
– The round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners.
– In conjunction with the funding, Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.
– The company intends to use the funds for development of its tumor diagnostic solutions and the expansion of sales.

Biotechnology Genetics Health Care Health Diagnostics Information Technology Life Science North America Personal Health
Crunchbase icon

Content report

The following text will be sent to our editors: